Napredna pretraga

Pregled bibliografske jedinice broj: 1003209

Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies


(STARK Project - Pancreas 2000 Program) Poropat, Goran; Archibugi, Livia; Korpela, Taija; Cardenas-Jaen, Karina; de-Madaria, Enrique; Capurso, Gabriele
Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies // United European Gastroenterology Journal, 6 (2018), 8; 1206-1214 doi:10.1177/2050640618781168 (međunarodna recenzija, članak, znanstveni)


Naslov
Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies

Autori
Poropat, Goran ; Archibugi, Livia ; Korpela, Taija ; Cardenas-Jaen, Karina ; de-Madaria, Enrique ; Capurso, Gabriele

Kolaboracija
STARK Project - Pancreas 2000 Program

Izvornik
United European Gastroenterology Journal (2050-6406) 6 (2018), 8; 1206-1214

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Acute pancreatitis ; case-control ; cohort ; meta-analysis ; risk ; statins

Sažetak
BACKGROUND: Statins are perceived as potential etiological factors for acute pancreatitis (AP), but recent evidence suggests the opposite. Our aim was to evaluate the association between statin use and risk of AP in observational studies. METHODS: Medline, Scopus, and Web of Science were searched for cohort (C) and case-control (CC) studies evaluating statins as intervention and AP as outcome. Pooled adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated. RESULTS: Thirteen studies (seven CC, six C) with 34, 899 AP patients and 5, 377, 894 controls were included. Prevalence of statin use was 9.8% among AP patients and 25% among controls. Pooled adjusted OR was 1.00 (95% CI = 0.63 to 1.59) with considerable heterogeneity (I 2 = 98%). CC studies were associated with increased AP risk (OR = 1.33 ; 95% CI = 1.20 to 1.47), unlike C studies (OR = 0.69 ; 95% CI = 0.37 to 1.31). No association with increased risk was found for studies from Western countries (OR = 0.90 ; 95% CI = 0.52 to 1.56), unlike for studies conducted in Asia (OR = 1.39 ; 95% CI = 1.10 to 1.75). CONCLUSION: Statin use is not associated with increased risk of AP. Increased risk was limited to CC studies, which are more prone to bias, while C studies showed no global effect. Further research is needed to clarify whether statin type, dosage, treatment duration or AP etiology might account for this difference.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka

Autor s matičnim brojem:
Goran Poropat, (303065)

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati